196 related articles for article (PubMed ID: 24262193)
1. Aldehyde dehydrogenase inhibition generates a reactive dopamine metabolite autotoxic to dopamine neurons.
Doorn JA; Florang VR; Schamp JH; Vanle BC
Parkinsonism Relat Disord; 2014 Jan; 20 Suppl 1(0 1):S73-5. PubMed ID: 24262193
[TBL] [Abstract][Full Text] [Related]
2. Products of oxidative stress inhibit aldehyde oxidation and reduction pathways in dopamine catabolism yielding elevated levels of a reactive intermediate.
Jinsmaa Y; Florang VR; Rees JN; Anderson DG; Strack S; Doorn JA
Chem Res Toxicol; 2009 May; 22(5):835-41. PubMed ID: 19388687
[TBL] [Abstract][Full Text] [Related]
3. Lipid peroxidation products inhibit dopamine catabolism yielding aberrant levels of a reactive intermediate.
Rees JN; Florang VR; Anderson DG; Doorn JA
Chem Res Toxicol; 2007 Oct; 20(10):1536-42. PubMed ID: 17887726
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of the oxidative metabolism of 3,4-dihydroxyphenylacetaldehyde, a reactive intermediate of dopamine metabolism, by 4-hydroxy-2-nonenal.
Florang VR; Rees JN; Brogden NK; Anderson DG; Hurley TD; Doorn JA
Neurotoxicology; 2007 Jan; 28(1):76-82. PubMed ID: 16956664
[TBL] [Abstract][Full Text] [Related]
5. Rotenone decreases intracellular aldehyde dehydrogenase activity: implications for the pathogenesis of Parkinson's disease.
Goldstein DS; Sullivan P; Cooney A; Jinsmaa Y; Kopin IJ; Sharabi Y
J Neurochem; 2015 Apr; 133(1):14-25. PubMed ID: 25645689
[TBL] [Abstract][Full Text] [Related]
6. Determinants of buildup of the toxic dopamine metabolite DOPAL in Parkinson's disease.
Goldstein DS; Sullivan P; Holmes C; Miller GW; Alter S; Strong R; Mash DC; Kopin IJ; Sharabi Y
J Neurochem; 2013 Sep; 126(5):591-603. PubMed ID: 23786406
[TBL] [Abstract][Full Text] [Related]
7. Dopamine-derived biological reactive intermediates and protein modifications: Implications for Parkinson's disease.
Jinsmaa Y; Florang VR; Rees JN; Mexas LM; Eckert LL; Allen EM; Anderson DG; Doorn JA
Chem Biol Interact; 2011 Jun; 192(1-2):118-21. PubMed ID: 21238438
[TBL] [Abstract][Full Text] [Related]
8. 3,4-Dihydroxyphenylacetaldehyde potentiates the toxic effects of metabolic stress in PC12 cells.
Lamensdorf I; Eisenhofer G; Harvey-White J; Nechustan A; Kirk K; Kopin IJ
Brain Res; 2000 Jun; 868(2):191-201. PubMed ID: 10854571
[TBL] [Abstract][Full Text] [Related]
9. Impaired dopamine metabolism in Parkinson's disease pathogenesis.
Masato A; Plotegher N; Boassa D; Bubacco L
Mol Neurodegener; 2019 Aug; 14(1):35. PubMed ID: 31488222
[TBL] [Abstract][Full Text] [Related]
10. The catecholaldehyde hypothesis: where MAO fits in.
Goldstein DS
J Neural Transm (Vienna); 2020 Feb; 127(2):169-177. PubMed ID: 31807952
[TBL] [Abstract][Full Text] [Related]
11. Benomyl, aldehyde dehydrogenase, DOPAL, and the catecholaldehyde hypothesis for the pathogenesis of Parkinson's disease.
Casida JE; Ford B; Jinsmaa Y; Sullivan P; Cooney A; Goldstein DS
Chem Res Toxicol; 2014 Aug; 27(8):1359-61. PubMed ID: 25045800
[TBL] [Abstract][Full Text] [Related]
12. The Catecholaldehyde Hypothesis for the Pathogenesis of Catecholaminergic Neurodegeneration: What We Know and What We Do Not Know.
Goldstein DS
Int J Mol Sci; 2021 Jun; 22(11):. PubMed ID: 34206133
[TBL] [Abstract][Full Text] [Related]
13. Comparison of Monoamine Oxidase Inhibitors in Decreasing Production of the Autotoxic Dopamine Metabolite 3,4-Dihydroxyphenylacetaldehyde in PC12 Cells.
Goldstein DS; Jinsmaa Y; Sullivan P; Holmes C; Kopin IJ; Sharabi Y
J Pharmacol Exp Ther; 2016 Feb; 356(2):483-92. PubMed ID: 26574516
[TBL] [Abstract][Full Text] [Related]
14. Methylmercury impairs canonical dopamine metabolism in rat undifferentiated pheochromocytoma (PC12) cells by indirect inhibition of aldehyde dehydrogenase.
Tiernan CT; Edwin EA; Hawong HY; Ríos-Cabanillas M; Goudreau JL; Atchison WD; Lookingland KJ
Toxicol Sci; 2015 Apr; 144(2):347-56. PubMed ID: 25601988
[TBL] [Abstract][Full Text] [Related]
15. Dihydroxyphenylacetaldehyde Lowering Treatment Improves Locomotor and Neurochemical Abnormalities in the Rat Rotenone Model: Relevance to the Catecholaldehyde Hypothesis for the Pathogenesis of Parkinson's Disease.
Khashab R; Gutman-Sharabi N; Shabtai Z; Landau R; Halperin R; Fay-Karmon T; Leibowitz A; Sharabi Y
Int J Mol Sci; 2023 Aug; 24(15):. PubMed ID: 37569897
[TBL] [Abstract][Full Text] [Related]
16. Oligomerization and Membrane-binding Properties of Covalent Adducts Formed by the Interaction of α-Synuclein with the Toxic Dopamine Metabolite 3,4-Dihydroxyphenylacetaldehyde (DOPAL).
Follmer C; Coelho-Cerqueira E; Yatabe-Franco DY; Araujo GD; Pinheiro AS; Domont GB; Eliezer D
J Biol Chem; 2015 Nov; 290(46):27660-79. PubMed ID: 26381411
[TBL] [Abstract][Full Text] [Related]
17. Inhibition and covalent modification of tyrosine hydroxylase by 3,4-dihydroxyphenylacetaldehyde, a toxic dopamine metabolite.
Mexas LM; Florang VR; Doorn JA
Neurotoxicology; 2011 Aug; 32(4):471-7. PubMed ID: 21514317
[TBL] [Abstract][Full Text] [Related]
18. Decreased vesicular storage and aldehyde dehydrogenase activity in multiple system atrophy.
Goldstein DS; Sullivan P; Holmes C; Kopin IJ; Sharabi Y; Mash DC
Parkinsonism Relat Disord; 2015 Jun; 21(6):567-72. PubMed ID: 25829070
[TBL] [Abstract][Full Text] [Related]
19. Protein reactivity of 3,4-dihydroxyphenylacetaldehyde, a toxic dopamine metabolite, is dependent on both the aldehyde and the catechol.
Rees JN; Florang VR; Eckert LL; Doorn JA
Chem Res Toxicol; 2009 Jul; 22(7):1256-63. PubMed ID: 19537779
[TBL] [Abstract][Full Text] [Related]
20. In vitro inhibition of glutathione-S-transferase by dopamine and its metabolites, 3,4-dihydroxyphenylacetaldehyde and 3,4-dihydroxyphenylacetic acid.
Crawford RA; Bowman KR; Cagle BS; Doorn JA
Neurotoxicology; 2021 Sep; 86():85-93. PubMed ID: 34314733
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]